DDInter285 DDInter1376
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Capecitabine {u} (Compound) treats {v} (Disease) colon cancer
Capecitabine {u} (Compound) binds {v} (Gene) TYMS
Capecitabine {u} (Compound) upregulates {v} (Gene) MCOLN1
Capecitabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Capecitabine {u} (Compound) causes {v} (Side Effect) Tonsillitis
Capecitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Capecitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Capecitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Capecitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Capecitabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Capecitabine (Compound) treats colon cancer (Disease)
Capecitabine (Compound) binds TYMS (Gene)
Capecitabine (Compound) upregulates MCOLN1 (Gene)
Capecitabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Capecitabine (Compound) causes Tonsillitis (Side Effect)
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Capecitabine may lead to a major life threatening interaction when taken with Cladribine